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Abstract 
 
Background: Bone morphogenetic protein receptor type 2 (BMPR2) mutations are present in 
patients with heritable and idiopathic pulmonary arterial hypertension (PAH).  Circulating levels of 
Interleukin-1 (IL-1) are raised in patients and animal models. Whether interplay between BMP and IL-
1 signalling can explain the local manifestation of PAH in the lung remains unclear. Methods: Cell 
culture, siRNA and mRNA microarray analysis of RNA isolated from human Pulmonary artery 
(PASMC) and Aortic (AoSMC) smooth muscle cells were used. R899X+/- BMPR2 transgenic mice fed 
western diet for six weeks were given daily injections of IL-1ß prior to assessment for PAH and tissue 
collection.  Results: PASMC have reduced inflammatory activation in response to IL-1ß compared 
with AoSMCs, however PASMC with reduced BMPR2 demonstrated an exaggerated response. Mice 
treated with IL-1ß had higher white blood cell counts, and significantly raised serum protein levels of 
IL-6 and OPG plasma levels recapitulating in vitro data.  Phenotypically, IL-1ß treated mice 
demonstrated increased pulmonary vascular remodelling. Conclusions: IL-1ß induces an 
exaggerated pulmonary artery specific transcriptomic inflammatory response when BMPR2 signalling 
is reduced.  
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Pulmonary arterial hypertension (PAH) is driven by vasoconstriction, inflammatory cell infiltration, 
vascular cell migration, proliferation and apoptosis.1 Molecular mechanisms regulating PAH 
pathogenesis are multifactorial involving potassium channels, genetic mutations, serotonin 
imbalances, oestradiol changes and inflammatory alterations amongst others.2, 3  
 
Vascular remodelling in PAH is confined to the lung and patients with the disease do not exhibit 
alterations in systemic blood pressure or peripheral vascular pathology.4 This observation indicates 
that inherent differences in the cellular behaviour in the vascular beds could potentially be one of the 
possible reasons why global BMPR2 changes only lead to pathogenic remodelling of the pulmonary 
vasculature whilst the systemic vessels remain unaltered. 
 
BMPR2 mutations are the primary genetic risk for PAH implicated in over 70% of heritable and 25% 
of sporadic cases, however disease penetrance even within families is low (around 15%).5 
Inflammatory diseases are associated with PAH, and levels of the pro-inflammatory cytokine 
interleukins (IL)1/6 are increased in PAH.6 IL-6 over-expression in vascular cells is sufficient to 
induce pulmonary vessel remodelling and PAH in a rodent model.7  Inflammation has been shown to 
be increased in patients and a link with BMPR2 deficiency has been considered.8 Previous animal 
studies have demonstrated that monocrotaline (MCT) induced PAH is prevented by administration of 
IL-1 receptor antagonist 9 and that Apolipoprotein-E knockout mice develop PAH in an IL-1 
dependent manner, and via a lung specific putative IL-1R1 receptor .10 Interestingly, recent data 
demonstrated that mice with a heterozygous mutation in BMPR2 have an increased inflammatory 
response to Lipopolysaccharide.11 Further recent literature indicates that the IL1R1/MyD88 signalling 
pathway is critical to development of animal models of PAH.12 We therefore hypothesised that under 
conditions of reduced BMPR2 expression/signalling, IL-1ß can act as a pulmonary specific disease 
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modifying secondary stimulus, thereby demonstrating a direct link between IL-1ß, BMPR2 and 
disease pathogenesis. 
 
Methods 
 
Smooth muscle cell culture and transfection 
 
Human pulmonary artery (hPASMC) (Lonza CC-2581) from a total of 3 commercial donors and 
four primary donors including those with and without disease related BMPR2 mutations and 
human aortic smooth muscle cells (hAoSMC) (Lonza CC-2571) from a total of 2 donors were 
maintained in smooth muscle cell media SmGM-2 including bullet kit supplements (Lonza CC-3182). 
All experiments were performed between passages 4 and 8.  Quiescent media (Dulbecco’s modified 
eagles medium (Lonza 12-604) with 0.2% (v/v) foetal bovine serum ((FBS) Lonza 14-401) was added 
for 48 hours prior to transfection with siRNA/reporter plasmid (Qiagen Cignal NFkB luciferase 
reporter) and/or 6 hour stimulation with IL-1ß at 10 ng/ml or BMP4 at 20 ng/ml. 13,14 
 
RNA extraction  
 
RNA was isolated using Trizol, Direct-zol RNA mini prep kits (Zymo research R2050) and Zymospin 
column as per manufacturer’s instructions. Eluted RNA quality was assessed using the Agilent 
Bioanalyzer 2100.  
 
Microarray and Bioinformatic Analysis 
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3-sample RNA pools were run per sub-array with three individual RNA pool sub-arrays per condition.  
Agilent microarray was performed (Agilent 5190-2305, 5188-5282, 5188-5242, 5188-5327and 
RNeasy mini kit, Qiagen 74104) following the Labelling protocol (version 6.6, September 2012 Agilent 
technologies, G4140-90040) per manufacturer’s instructions and scanned using the Agilent G2565BA 
scanner. 
 
Data analysis was performed using the Bioconductor package Limma in the programing language 
“R”. Targets files were created containing Agilent G2565BA microarray scanner output files. 
Background correction, cyclic loess normalisation and averaging of repeats was performed.  A linear 
modelling matrix was built and fitted.  Gene lists were filtered discarding those unaltered by IL-1ß in 
the order of a log2 fold change of <1 and for an adjusted p value of <0.05.  A pathway analysis 
functional output was obtained using Signalling Pathway Impact Analysis (SPIA) in R. All as 
described in previous papers from our group. 13 A 2-dimensional projection of the microarray 
expression data was generated using the non-parametric dimensionality reduction.  This was 
achieved using the t-distributed stochastic neighbor embedding (t-SNE) algorithm in the R 
package Rtse. The resulting t-SNE output was plotted with R package ggplot2.   The array data 
will be deposited in NCBI’s Gene Expression Omnibus. 
 
Luciferase reporter assay 
 
Following 48 hours incubation with siRNA, reporter plasmid and stimulants, cells were lysed 
and firefly and renila luciferase was read using Promega dual glo assay as per manufacturers 
instruction and read using the Varioskan Plate reader. 
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Real-Time Polymerase Chain Reaction of Cellular mRNA samples 
 
RNA (n=9-17 for each condition) was reverse transcribed to cDNA using RNA to cDNA kit 
(Applied Biosystems 4387406). TaqMan probes for BMPR2 Hs00176148, IL-6 Hs1075666, SOD2 
Hs00167309, OPG Hs00917067, VIPR1 Hs00910453 were purchased from Thermo fisher and 
run in duplicate. Human ribosomal 18S Hs99999901 was used as control. Relative Quantity was 
calculated using the Ct method.15 
 
Animal models  
 
Rosa26-rtTA2×TetO7-Bmpr2R899X mice called Rosa26-Bmpr2R899X were used with mutant 
expression induced by doxycycline as previously described.16  24 x Rosa26-Bmpr2R899X 
transgenic mice and 12 x C57 wild-type littermates were fed western diet for six weeks and injected 
with IL-1ß or placebo i.p. once daily for the final four weeks. Mice were assessed for inflammatory 
activation and PAH phenotype as previously described.17 Following 6 weeks of treatment the mice 
were given injectable anaesthesia for terminal surgery.  Animals underwent full haemodynamic 
phenotyping including echocardiography, right and left heart catheterisation, blood sampling by 
cardiac puncture and a full range of tissues taken and snap frozen.    All animal studies were pre-
approved by Vanderbilt University Institutional Animal Care and Use Committee.  
 
Enzyme Linked ImmunoSorbent Assay 
 
Mouse serum samples were run using assay DY805 (OPG) and DY206 (IL-6) as per manufacturer’s 
instructions.   
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Results 
 
IL-1ß stimulation and BMPR2 dysfunction elicit vascular bed specific transcriptional 
regulation in smooth muscle cells 
 
PAH is a pulmonary arterial specific disease suggesting that there may be vascular bed specific 
transcriptional regulation.  A major portion of the vascular disease pathology within the lesions is 
driven by the proliferation and migration of alpha smooth muscle actin (SMA) positive cells and we 
therefore sought to characterize, and compare the cellular signalling profile in smooth muscle actin 
positive cells from the pulmonary and aortic smooth muscle cells (PASMC and AoSMC). 1235 genes 
were significantly differentially expressed across both cell types in response to IL-ß, 444 in PASMC 
contrasting with 919 in AoSMCs. Of these genes 128 overlap in both cell types (Figure 1A).  
Subsequent Signalling Pathway Impact Analysis (SPIA) identified significant differences in the 
pathways represented by the genes specific to each cell type (SPIA graphs and tables for the genes 
specific to PA and Ao as supplemental Figure 1A and B respectively).  Comparison of the altered 
PASMC pathways highlighted differences in disease relevant pro-migratory and pro-proliferative 
pathways. “Pathways in Cancer” and infectious disease pathways were altered containing disease 
relevant wnt, FADD and MEK signalling.  These pathways were activated in the AoSMC cells but 
responses were either inhibited or suppressed in the PASMC (figure 1B). 
 
Microarray validation using repeat and separate donor cells was performed by quantitative reverse 
transcription-PCR on selected pathway and disease relevant genes 13.  Aortic smooth muscle cells 
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demonstrated greater increases in inflammatory genes than PASMC given the same stimulus.  All 
genes analysed validated array findings in terms of increase or decrease of gene expression 
although the degree of alteration varied between platforms.  Inflammatory and pro-apoptotic genes 
including IL-6 and OPG (Osteoprotegerin) are increased in AoSMCs to a larger extent than PASMCs. 
However, PASMCs demonstrated an increased baseline level of VIPR1 compared to AoSMCs but 
lost of expression when stimulated with IL-1ß. Disease relevant receptors were also measured. There 
were no changes to IL-1ß in PDGF receptors a or b (figure 1C). 
 
BMPR2 deficiency exaggerates inflammatory activation to IL-1ß stimulation in PASMC but not 
AoSMC 
 
The BMP and IL-1ß signalling pathways are linked through the co-localisation and co-expression of 
gene family members (http://www.genemania.com, supplemental figure 2) although the direct 
influence of one upon the other in PASMC is unknown. We sought to determine the effect of reduced 
BMPR2 expression in PASMCs using siRNA, and alterations induced by subsequent stimulation with 
IL-1ß, using whole genome microarray. Knock-down of BMPR2 was confirmed by rtPCR (figure 2A). 
Stimulation with IL-1ß resulted in the differential expression of 825 genes on the background of 
reduced BMPR2 expression compared to 524 in control non-targeting (Ntsi) siRNA treated cells 
(figure 2B). SPIA analysis highlighted changes in pathway activation in “pathways in cancer” and 
“rheumatoid arthritis” (SPIA graphs and tables for the genes specific to PA with and without functional 
BMPR2 as supplemental Figure 2a and b respectively).  Overall there were significant increases in 
the pro-inflammatory, pro-proliferative and migratory pathways activated most notably the massive 
increased activation of the cytokine and chemokine signalling pathways following IL-1ß stimulation in 
PASMCs where BMPR2 expression is reduced (figure 2C).  This is reflected in the t-SNE analysis 
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showing that the microarray data clusters into the conditions.  In non-targeting silencing RNA 
treated PASMCs the IL-1ß makes an alteration in clustering however this alteration is 
exaggerated in the presence on BMPR2 silencing RNA (figure 2D).   
 
For further evidence of interactions between the 2 pathways NFkB reporter plasmid (Qiagen 
Cignal NFkB luc reporter assay) was used to assess the changes in IL-1ß signaling through 
NFkB in the presence and absence of BMP pathway activation.  These experiments showed 
that activation of the BMP signaling pathway by stimulation with BMP4 repressed IL-
1ß stimulation of NFkB, however upon reduction of BMP signaling through the addition of 
silencing RNA to BMPR2 this NFkB signaling was restored (figure 2E). 
 
To consider the effects of reduced BMPR2 expression in PASMC, validation was performed on 
PASMC with and without transfection using silencing RNA to BMPR2. A small panel of genes was 
put together from a disease relevant gene list 13 to validate the microarray data that would cover the 
range expression changes observed. Minimal transcriptional changes were noted in the mock 
transfection samples (data not shown) however reduced BMPR2 expression combined with IL-
1ß stimulation caused a further increase in expression of the pro-inflammatory genes within the 
panel.  This is not the case in AoSMC with many genes being decreased upon reduced BMPR2 
expression, a summary of all the taqman carried out has been included (figure 3A). 
 
At the individual gene level, IL-1ß stimulation in conditions of reduced BMPR2 expression in PASMC 
resulted in a greater induction of IL-6 compared to normal BMPR2 expression in PASMC. Using the 
same regime, there was no change in IL-6 in Aortic cells or in PASMC taken from donors with and 
without known BMPR2 mutations (figure 3B). Loss of BMPR2 also caused large increases in the 
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expression of OPG regardless of IL-1 ß stimulation in PASMC but gave rise to a decrease of OPG in 
unstimulated Aortic cells which was reversed by IL-1ß stimulation, in donor cells increases were 
seen in OPG to IL-1ß stimulation regardless of their mutation status (figure 3C). VIPR1 in aortic 
cells is unaffected by loss of BMPR2 function however PASMC showed a significant increase at 
baseline which was normalised by IL-1ß.  PASMCs taken from donors display the same pattern 
as commercial PASMCs where loss of BMPR2 function induces a large increase in VIPR1 
expression which can be nomalised to an extent by IL-1ß  (figure 3D).   
 
Array validation by qPCR of receptor expression showed that expression of PDGF receptors in 
PAMSC increased to loss of BMPR2 expression but normalised to IL-1ß stimulation, this trend is 
also the case in donor PAMSCs in PDGFRA, whereas PDGFRB is increased in mutant patient 
cells regardless of IL-1ß stimulation. In AoSMC, however, loss of BMPR2 induces loss of 
PDGFRa and b expression (figure 3E and F).  
 
BMPR2 deficiency exaggerates inflammatory activation to IL-1ß stimulation in R899X+/- BMPR2 
transgenic mice fed high fat diet 
 
To determine if these in vitro observations were relevant in vivo we next investigated whether IL-
1ß supplementation alters PAH phenotype in BMPR2 mutant mouse overexpressing the mutation 
R899X in the BMPR2 gene.  These mice have been previously shown to have disrupted 
BMPR2 signaling.16 In accordance with the protocol outlined in figure 4A, Rosa26-Bmpr2R899X were 
given IL-1ß treatment. RVSP was unaffected however pulmonary vascular resistance (PVR) was 
increased in mutant mice treated with IL-1ß whilst systemic blood pressure was unaffected (figure 
4B). Modest increases in small pulmonary arteriole muscularisation and SMA and PCNA positive 
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cells (figure 4C) suggesting more advanced pulmonary vascular remodelling were also seen. Delivery 
of IL-1 ß was evidenced by the increased WBC counts. Serum levels of IL-6 were increased in 
mutant IL-1ß treated Rosa26-Bmpr2R899X animals. OPG was increased in response to IL-1ß 
regardless of mutation status (figure 4D).  
 
 
Discussion 
 
Using unbiased microarray analysis we report that IL-1ß induces vascular bed specific transcriptional 
regulation in SMCs. Control (Normal) PASMCs display reduced inflammatory activation to IL-1ß 
comparative to AoSMCs in vitro. mRNA and pathway analysis identified a dampened pro-
inflammatory, pro-proliferative response to IL-1ß in PASMCs compared to AoSMC which was lost 
upon loss of functional BMPR2. These findings are consistent with reports demonstrating beneficial 
effects of IL-1 receptor antagonist (IL-1ra) in animal models of PAH where BMPR2 is lowered such 
as the monocrotaline model.9 Furthermore, we demonstrate that BMPR2 signalling dysfunction 
results in increased inflammatory signalling and activation of mitogenic pathways such as PDGF 
which are inhibited in normal PASMC in-vitro but this does not occur in SMCs from the systemic 
vascular bed. This is an inherent part of the disease pathogenesis and our findings could go some 
way to explain why patients with BMPR2  mutations go on to develop pulmonary vascular 
remodelling without effects on their systemic vessels. 
 
These findings are confirmed in the cells from lung transplant patients with and without 
disease causing BMPR2 mutations. 
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We report for the first time the additive effect for the loss of BMPR2 and administration of IL-1ß on 
the catalogue of transcriptional activity. Mutant BMPR2 expression combined with IL-1ß caused 
raised PVR associated with increased small pulmonary vessel muscularisation and correlated 
positively with serum IL-6 levels. 
 
Therapeutic agents targeting IL-1ß are in clinical use, of note anakinra, which has recently been 
trialled in therapeutic use in PAH 18. This gives reason for further investigation in to the role IL-
1ß may play in disease and late stage clinical trials using biologics (canukinumab)19 in cardiovascular 
disease gives further emphasis for insights into this potential therapeutic area. 
 
Our data suggest that targeting IL-1ß may be an effective therapeutic strategy for PAH treatment and 
that patient stratification according to IL-1ß responsive signals could be useful for identifying patients 
with an increased likelihood of treatment response.  An advantage of targeting IL-1ß specifically is 
that this may mitigate against the risk of opportunistic infection by allowing other IL-1 to participate in 
host defence.20 Other recent research has shown that targeting inflammatory signalling in 
combination with increasing BMPR2 function is helpful in the treatment of PAH by the use in animal 
models of the drug FK506 (Tacrolimus)21 and a subsequent phase IIa clinical trial.22  
 
 Manipulation of inflammatory cell infiltration and endothelial cell apoptosis by antagonizing the BLT1 
receptor of leukotriene LTB4 has also been shown to be effective in-vivo
23 which backs up our 
findings that a combination of inflammation and BMPR2 dysfunction is important.  Interestingly, the 
importance of neutrophil elastase (NE) in the pathobiology of PAH has been well recognized24 and 
recent work demonstrating NE mediated release of IL-1ß25 may provide further evidence for a central 
role of IL-1ß biology in the pathogenesis of PAH, and highlights additional evidence for the potential 
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use of NE inhibitors in PAH. 
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Pathway analysis performed using signalling pathway impact analysis (SPIA) 
pathway analysis software on IL-1ß stimulated in PASMC (a) AoSMCs (b) and 
PASMC in the presence of siRNA to BMPR2 (c) using SPIA code in R all gene 
information from arrays are taken into account and cross-referenced against 
known pathways. The Y-axis shows degree of perturbation against the X-axis 
plotting the number of differential expressed genes and each point on the graph 
is pathway expressed as a pathway number with decode table also shown. 
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Protein interactions in the IL-1ß and BMPR2 pathways.  BMP and IL-1ß 
signalling pathways are linked through the co-localisation and co-expression of 
gene family members (http://www.genemania.com) 
 
 
 
 
 
